Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit.
The company's Founder, President, and CEO, Dr. Laxminarayan Bhat, will deliver a webcasted presentation on Monday, January 13, 2025, at 12:30 p.m. ET. The virtual event will be accessible through the conference homepage at lythampartners.com/health2025/ or directly via the company-specific link.
Investors will have the opportunity to schedule one-on-one meetings following the event by contacting Lytham Partners representatives. A replay of the presentation will be made available through the same web links.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una società farmaceutica in fase avanzata focalizzata sullo sviluppo di terapie per malattie del sistema nervoso centrale (CNS), infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione al prossimo Summit Sanitario per Investitori Lytham Partners 2025.
Il fondatore, presidente e CEO della società, Dr. Laxminarayan Bhat, terrà una presentazione in diretta streaming lunedì 13 gennaio 2025, alle 12:30 ET. L'evento virtuale sarà accessibile tramite la homepage della conferenza all'indirizzo lythampartners.com/health2025/ o direttamente tramite il link specifico della società.
Gli investitori avranno l'opportunità di fissare incontri individuali dopo l'evento contattando i rappresentanti di Lytham Partners. Una registrazione della presentazione sarà disponibile tramite gli stessi link web.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en el desarrollo de terapias para enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas, ha anunciado su participación en el próximo Cumbre de Atención Médica para Inversores Lytham Partners 2025.
El fundador, presidente y director ejecutivo de la empresa, Dr. Laxminarayan Bhat, ofrecerá una presentación transmitida por webcast el lunes 13 de enero de 2025, a las 12:30 p.m. ET. El evento virtual será accesible a través de la página principal de la conferencia en lythampartners.com/health2025/ o directamente a través del enlace específico de la empresa.
Los inversores tendrán la oportunidad de programar reuniones uno a uno después del evento contactando a los representantes de Lytham Partners. Una repetición de la presentación estará disponible a través de los mismos enlaces web.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)는 중추 신경계 (CNS), 염증 및 심대사 질환 치료제를 개발하는 데 주력하는 후 단계 제약 회사로, 다가오는 Lytham Partners 2025 투자자 건강 관리 서밋에 참여할 것이라고 발표했습니다.
회사의 설립자이자 사장, CEO인 Dr. Laxminarayan Bhat는 2025년 1월 13일 월요일 오후 12시 30분(ET)에 웹캐스트 발표를 진행할 예정입니다. 이 가상 이벤트는 lythampartners.com/health2025/의 컨퍼런스 홈페이지를 통해 접근할 수 있습니다. 또는 회사 전용 링크를 통해서도 가능합니다.
투자자들은 행사 후 Lytham Partners 대표와 연락하여 일대일 미팅을 예약할 수 있는 기회를 갖게 됩니다. 발표의 재방송은 동일한 웹 링크를 통해 제공될 것입니다.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée concentrée sur le développement de thérapies pour les maladies du système nerveux central (CNS), inflammatoires et cardiométaboliques, a annoncé sa participation au prochain Sommet de la santé pour investisseurs de Lytham Partners 2025.
Le fondateur, président et PDG de l'entreprise, Dr. Laxminarayan Bhat, fera une présentation en webcast le lundi 13 janvier 2025, à 12h30 HE. L'événement virtuel sera accessible via la page d'accueil de la conférence à l'adresse lythampartners.com/health2025/ ou directement via le lien spécifique à l'entreprise.
Les investisseurs auront l'occasion de programmer des réunions individuelles après l'événement en contactant les représentants de Lytham Partners. Un enregistrement de la présentation sera disponible via les mêmes liens web.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), ein Pharmaunternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung von Therapien für krankheiten des zentralen Nervensystems (CNS), entzündliche sowie kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme am bevorstehenden Lytham Partners 2025 Investor Healthcare Summit angekündigt.
Der Gründer, Präsident und CEO des Unternehmens, Dr. Laxminarayan Bhat, wird am Montag, den 13. Januar 2025, um 12:30 Uhr ET eine webcast-Präsentation halten. Die virtuelle Veranstaltung wird über die Homepage der Konferenz unter lythampartners.com/health2025/ oder direkt über den unternehmensspezifischen Link zugänglich sein.
Investoren haben die Möglichkeit, persönliche Meetings nach der Veranstaltung zu vereinbaren, indem sie sich an die Vertreter von Lytham Partners wenden. Eine Wiederholung der Präsentation wird über dieselben Weblinks bereitgestellt.
- None.
- None.
CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Company Webcast
The webcasted presentation will take place at 12:30 p.m. ET on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/rvph. A replay of the presentation will also be available through same links.
1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at RVPH@LythamPartners.com.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva's (RVPH) presentation at the Lytham Partners Healthcare Summit 2025?
How can investors access RVPH's presentation at the Lytham Partners Summit?
What therapeutic areas does Reviva (RVPH) focus on?
How can investors arrange 1x1 meetings with Reviva (RVPH) management?
